T2 Biosystems (TTOO)
(Delayed Data from NSDQ)
$2.19 USD
-0.01 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.28 +0.09 (4.11%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for T2 Biosystems, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 22 | 28 | 18 | 8 |
Cost Of Goods | 15 | 21 | 21 | 21 | 17 |
Gross Profit | -8 | 1 | 7 | -3 | -8 |
Selling & Adminstrative & Depr. & Amort Expenses | 41 | 56 | 50 | 38 | 44 |
Income After Depreciation & Amortization | -50 | -55 | -43 | -41 | -52 |
Non-Operating Income | 5 | -1 | 0 | 0 | 0 |
Interest Expense | 5 | 6 | 7 | 6 | 7 |
Pretax Income | -50 | -62 | -49 | -47 | -59 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -50 | -62 | -49 | -47 | -59 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -50 | -62 | -49 | -47 | -59 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -49 | -53 | -40 | -38 | -48 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 3 | 3 | 4 |
Income After Depreciation & Amortization | -50 | -55 | -43 | -41 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.61 | 0.05 | 0.03 | 0.02 | 0.01 |
Diluted EPS Before Non-Recurring Items | -19.19 | -1,228.00 | -1,550.00 | -1,950.00 | -6,500.00 |
Diluted Net EPS (GAAP) | -19.19 | -1,222.00 | -1,550.00 | -1,950.00 | -6,500.00 |
Fiscal Year end for T2 Biosystems, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.95 | 2.06 | 1.68 | 1.47 | 1.96 |
Cost Of Goods | 2.69 | 4.20 | 2.57 | 3.93 | 4.87 |
Gross Profit | -0.74 | -2.14 | -0.90 | -2.45 | -2.91 |
SG&A, R&D, and Dept/Amort Expenses | 8.83 | 10.46 | 8.43 | 11.15 | 10.15 |
Income After SG&A, R&D, and Dept/Amort Expenses | -9.57 | -12.60 | -9.33 | -13.60 | -13.06 |
Non-Operating Income | 1.09 | 0.25 | 0.14 | -0.70 | 8.25 |
Interest Expense | 0.48 | 1.18 | 1.16 | 1.12 | 1.54 |
Pretax Income | -8.96 | -13.53 | -10.34 | -15.43 | -6.35 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.96 | -13.53 | -10.34 | -15.43 | -6.35 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.96 | -13.53 | -10.34 | -15.43 | -6.35 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 14.10 | 5.10 | NA | 4.48 | 0.81 |
Diluted EPS Before Non-Recurring Items | -0.66 | -2.66 | NA | -3.45 | -8.00 |
Diluted Net EPS (GAAP) | -0.64 | -2.66 | 124.26 | -3.45 | -8.00 |